# This Page Is Inserted by IFW Operations and is not a part of the Official Record

# **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

# IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

WO 96/043




FIGURE 1




FIGURE 2






FIGURE 3


Pvu I

Sca I


EcoR I Not I Fsp I 13 Kon I EcoR V Hind III 11k gpt R-tk L-tk pvHCV-11A Xba I. ori Nhe I 5900 bp F1(-) Amp Bal I


FIGURE 4







weeks after start of treatment













weeks after start of treatment











# FIGURE 14

LOBUSTUL IOVOGIL

Competition of reactivity of anti-E1 Mabs with peptides




COUCATON CYCETA




O 3a dl M ▲ P 1b Anti-E1 (epitope 1) levels in RESPONDERS to IFN treatment 80 55 60 65 70 75 20 weeks after start of treatment 10 15 20 25 30 35 40 45 SERIES 1 S 0 5 N/S 9 0 Θ ~ 7


CTESSELL CYCES




WO 96/04385



CTWVVILL CYCTL







### Figure 21

- 5' GGCATGCAAGCTTAATTAATT3' (SEQ ID NO 1)
  3'ACGTCCGTACGTTCGAATTAATTAATCGA5' (SEQ ID NO 94)
- 5'CCGGGGAGGCCTGCACGTGATCGAGGGCAGACACCATCACCACCATCACTAATAGT TAATTAACTGCA 3' (SEQ ID NO 2)

### SEC ID NO 3 (HCCISA)

### SEQ ID NO 5 (HCCI10A)



### SEQ ID NO 7 (HCCI11A)

### SEQ ID NO 9 (HCCI12A)

### SEQ ID NO 11 (HCCI13A)



SEQ ID NO 13 (HCCI17A)

SEQ ID NO 15 (HCPr51)
ATGCCCGGTTGCTCTTTCTCTATCTT

SEQ ID NO 16 (HCPr52)

ATGTTGGGTAAGGTCATCGATACCCT

SEQ ID NO 17 (HCPr53)
CTATTAGGACCAGTTCATCATCATATCCCA

SEQ ID NO 18 (HCPr54)
CTATTACCAGTTCATCATCATATCCCA

SEQ ID NO 19 (HCPr107)

ATACGACGCCACGTCGATTCCCAGCTGTTCACCATC



SEQ ID NO 20 (HCPr108)

GATGGTGAACAGCTGGGAATCGACGTGGCGTCGTAT

### SEQ ID NO 21 (HCCI37)

### SEQ ID NO 23 (HCC138)

### SEQ ID NO 25 (HCC139)

TAG

ATGTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA
TTCCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG
GGTTCTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT



ATCTTCCTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG
CAACGTGTCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTAT
GAGGCAGCGGACATGATCATGCACACCCCCGGGTGCCCTGCGTTCGGGAGAAC
AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG
TCCCCACCACGACAATACGACGCCACGTCGATTCCCAGCTGTTCACCATCTCGCCTCG
CCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGT
CACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCTACAACGGCCCTGGTGGTAT
CGCAGCTGCTCCGGATCCTCAATAG

### SEQ ID NO 27 (HCC140)

### SEQ ID NO 29 (HCC162)

ATGGGTAAGGTCATCGATACCCTTACGTGCGGATTCGCCGATCTCATGGGGTACATCC
CGCTCGTCGGCGCTCCCGTAGGAGGCGTCGCAAGAGCCCTTGCGCATGGCGTGAGGGC
CCTTGAAGACGGGATAAATTTCGCAACAGGGAATTTGCCCGGTTGCTCCTTTTCTATTT
TCCTTCTCGCTCTGTTCTCTTGCTTAATTCATCCAGCAGCTAGTCTAGAGTGGCGGAAT
ACGTCTGGCCTCTATGTCCTTACCAACGACTGTTCCAATAGCAGTATTGTGTACGAGGC
CGATGACGTTATTCTGCACACACCCCGGCTGCATACCTTGTGTCCAGGACGGCAATACA
TCCACGTGCTGGACCCCAGTGACACCTACAGTGGCAGTCAAGTACGTCGGAGCAACCA
CCGCTTCGATACGCAGTCATGTGGACCTATTAGTGGGCGCGGCCACGATGTGCTCTGC
GCTCTACGTGGGTGACATGTGTGGGGCTGTCTTCCTCGTGGGACAAGCCTTCACGTTCA
GACCTCGTCGCCATCAAACGGTCCAGACCTGTAACTGCTCGCTGTACCCAGGCCATCT
TTCAGGACATCGAATGGCTTGGGATATGATGATGAACTGGTAATAG




SEQ ID NO 31 (HCCl63)

ATGGGTAAGGTCATCGATACCCTAACGTGCGGATTCGCCGATCTCATGGGGTATATCC
CGCTCGTAGGCGGCCCCATTGGGGGGCCTCGCAAGGGCTCTCGCACACGGTGTGAGGGT
CCTTGAGGACGGGGTAAACTATGCAACAGGGAATTTACCCGGTTGCTCTTTCTCTATCT
TTATTCTTGCTCTTCTCTCGTGTCTGACCGTTCCGGCCTCTGCAGTTCCCTACCGAAATG
CCTCTGGGATTTATCATGTTACCAATGATTGCCCAAACTCTTCCATAGTCTATGAGGCA
GATAACCTGATCCTACACGCACCTGGTTGCGTGCCTTGTGTCATGACAGGTAATGTGA
GTAGATGCTGGGTCCAAATTACCCCTACACTGTCAGCCCCGAGCCTCGGAGCAGTCAC
GGCTCCTCTTCGGAGAGCCGTTGACTACCTAGCGGGAGGGGCTGCCCTCTGCTCCGCG
TTATACGTAGGAGACCGCTTGGGGACACTGTTCCATTTACAGTGGCCATGT
TACCGGCCACCGGATGGCATGGGGATATGATGATGAACTGGTAATAG

SEQ ID NO 33 (HCPr109)
TGGGATATGATGATGAACTGGTC

SEQ ID NO 34 (HCPr72)
CTATTATGGTGGTAAKGCCARCARGAGCAGGAG

SEQ ID NO 35 (HCCL22A)




### SEQ ID NO 37 (HCCI41)

GATCCCACAAGCTGTCGTGGACATGGTGGCGGGGGCCCATTGGGGAGTCCTGGCGG CCTCGCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCT TTGCCGGCGTCGACGGGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCA GGGGCCTTGTGTCCCTCTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACAC AGGGTTCTTTGCCGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAG CGCTTGGCCAGCTGTCGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTT ACACTGAGCCTAACAGCTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACC GTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCC CGACTCGGATGTGCTGATTCTCAACAACACGCGGCCGCCGCGAGGCAACTGGTTCGGC TGTACATGGATGAATGGCACTGGGTTCACCAAGACGTGTGGGGGCCCCCCGTGCAACA CGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTT CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGT TAGGATGTACGTGGGGGGGGGGGGGCACAGGTTCGAAGCCGCATGCAATTGGACTCG AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTG TCTACAACAGAGTGGCAGAGTGAGCTTAATTAATTAG

### SEQ ID NO 39 (HCC142)


GATCCCACAAGCTGTCGTGGACATGGTGGCGGGGGCCCATTGGGGAGTCCTGGCGGGCCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCT



TTGCCGGCGTCGACGGGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCA GGGGCCTTGTGTCCCTCTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACAC CAACGGCAGTTGGCACACACACGACTCCCAAAC AGGGTTCTTTGCCGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAG CGCTTGGCCAGCTGTCGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTT ACACTGAGCCTAACAGCTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACC GTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCC CTGTTGTGGTGGGGGACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAA CGACTCGGATGTGCTGATTCTCAACAACACGCGGCGCCGCGAGGCAACTGGTTCGGC TGTACATGGATGAATGGCACTGGGTTCACCAAGACGTGTGGGGGGCCCCCCGTGCAACA CGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTT CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGT TAGGATGTACGTGGGGGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCG AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTG TCTACAACAGGTGATCGAGGGCAGACACCATCACCACCATCACTAATAG

### SEQ ID NO 41 (HCCI43)

ATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACG GGCATACCCGCGTGTCAGGAGGGGCAGCCAGCCTCCGATACCAGGGGCCTTGTGTCCCT CTTTAGCCCCGGGTCGGCTCAGAAATCCAGCTCGTAAACACCAACGGCAGTTGGCAC ATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCAC TATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCG CTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGC TCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCG CGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGAC ATTCTCAACAACACGCGGCCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATG GCACTGGGTTCACCAAGACGTGTGGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCA ACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGC CAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGG CTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGG GGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGA CTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGTCTACAACAGAGTGG CAGAGCTTAATTAATTAG



SEQ ID NO 43 (HCCI44)

ATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACG GGCATACCCGCGTGTCAGGAGGGGCCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCT CTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCAC ATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCAC TATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCG CTCCATCGACAAGTTCGCTGAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGC TCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCG CGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGAC ATTCTCAACAACACGCGGCCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATG GCACTGGGTTCACCAAGACGTGTGGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCA ACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGC CAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGG CTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGG GGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGA CTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGTCTACAACAGGTGAT CGAGGCAGACACCATCACCATCACTAATAG

### SEQ ID NO 45 (HCCL64)



### SEQ ID NO 47 (HCC165)

AATTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA TTCCGCTCGTCGGCGCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG GGTTCTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT ATCTTCCTCTTGGCTTTGCTGTCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG CAACGTGTCCGGGATGTACCATGTCACGAACGACTGCAACTCAAGCATTGTGTAT GAGGCAGCGGACATGATCATGCACACCCCGGGTGCGTGCCCTGCGTTCGGGAGAAC AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG TCCCCACCACGACAATACGACGCCACGTCGATTTGCTCGTTGGGGGCGGCTGCTTTCTG TTCCGCTATGTACGTGGGGGACCTCTGCGGATCTGTCTTCCTCGTCTCCCAGCTGTTCA CCATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGG CCACATAACGGGTCACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCTACAACG GCCCTGGTGGTATCGCAGCTGCTCCGGATCCCACAAGCTGTCGTGGACATGGTGGCGG GGGCCCATTGGGGAGTCCTGGCGGGCCTCGCCTACTATTCCATGGTGGGGAACTGGGC TAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACGGGCATACCCGCGTGTCAG GAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCTCTTTAGCCCCGGGTCGGC TCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAACAGGACTGCCCT GAACTGCAACGACTCCCCAAACAGGGTTCTTTGCCGCACTATTCTACAAACACAAA TTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCGCTCCATCGACAAGTTCG CTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGGCCCTA CTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGT CCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGGACGACCGATCGGTTTGGTGT CCCCACGTATAACTGGGGGGGGGAACGACTCGGATGTGCTGATTCTCAACAACACGCGG CCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTCACCAAGA CGTGTGGGGGCCCCCGTGCAACATCGGGGGGGCCGGCAACACACCTTGACCTGCC

### SEQ ID NO 49 (HCC166)

ATGAGCACGAATCCTAAACCTCAAAGAAAACCAAACGTAACACCAACCGCCGCCCA CAGGACGTCAAGTTCCCGGGCGGTGGTCAGATCGTTGGTGGAGTTTACCTGTTGCCGC GCAGGGGCCCCAGGTTGGGTGTGCGCGCGACTAGGAAGACTTCCGAGCGGTCGCAAC CTCGTGGGAGGCGACCAACCTATCCCCAAGGCTCGCCGACCCGAGGGTAGGGCCTGGG CTCAGCCCGGGTACCCTTGGCCCCTCTATGGCAATGAGGGCATGGGGTGGGCAGGATG GCTCCTGTCACCCCGGGGTCTCGGCCTAGTTGGGGCCCTACAGACCCCCGGCGTAGG TCGCGTAATTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGG GGTACATTCCGCTCGTCGGCGCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGG CGTCCGGGTTCTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCT TTCTCTATCTTCCTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAA GTGCGCAACGTGTCCGGGATGTACCATGTCACGAACGACTGCAACTCAAGCATTG GAACAACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCC AGCGTCCCCACCACGACAATACGACGCCACGTCGATTTGCTCGTTGGGGCGGCTGCTT TCTGTTCCGCTATGTACGTGGGGGACCTCTGCGGATCTGTCTCCCCAGCTG TTCACCATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATC CCGGCCACATAACGGGTCACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCTAC AACGGCCCTGGTGGTATCGCAGCTGCTCCGGATCCCACAAGCTGTCGTGGACATGGTG GCGGGGGCCCATTGGGGGAGTCCTGGCGGGCCTCGCCTACTATTCCATGGTGGGGAACT GGGCTAAGGTTTTGGTGATGCTACTCTTTGCCGGCGTCGACGGGCATACCCGCGT GTCAGGAGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCTCTTTAGCCCCGGG



TCGGCTCAGAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAACAGGACT GCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCACTATTCTACAAAC ACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCGCTCCATCGACAA GTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGG CCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTCAGGTGT GCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGATCGGTT TGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCTCAACAAC ACGCGGCCGCCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTCA CCAAGACGTGTGGGGGCCCCCCGTGCAACACCTTGA CCTGCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTC TGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCACTAC CCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGGCGTGGAGC ACAGGTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACA GGGATAGATCAGAGCTTAGCCCGCTGCTGTCTACAACAGAGTGGCAGATACTGCC CTGTTCCTTCACCACCCTGCCGGCCCTATCCACCGGCCTGATCCACCTCCATCAGAAC ATCGTGGACGTGCAATACCTGTACGGTGTAGGGTCGGCGGTTGTCTCCCTTGTCATCA AATGGGAGTATGTCCTGTTGCTCTTCCTTCTCCTGGCAGACGCGCGCATCTGCGCCTGC TTATGGATGATGCTGATAGCTCAAGCTGAGGCCGCCTTAGAGAACCTGGTGGTCC GCTGCCTGGTACATCAAGGGCAGGCTGGTCCCTGGTGCGGCATACGCCTTCTATGGCG TGTGGCCGCTGCTCCTGCTGCCTGGCCTTACCACCACGAGCTTATGCCTAGTAA


IPEVELL TOTAL

Figure 22

OD measured at 450 nm construct

Fraction	volume dilution	39 Type Ib	40 Type Ib	62 Тург За	63 Type 5a
START FLOW THRO  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	23 ml 1/20 OUGH 23 ml 1/20 0.4 ml 1/200	2.517 0.087 0.102 0.396 2.627 3 3 2.694 2.408 2.176 1.461 1.286 0.981 0.812 0.812 0.373 0.653 0.441 0.321	1.954 0.085 0.051 0.550 2.603 2.967 2.810 2.499 2.481 1.970 1.422 0.926 0.781 0.650 0.432 0.371 0.348 0.374 0.186	1.426 0.176 0.048 0.090 2.481 3 2.640 1.359 0.347 1.624 0.887 0.543 0.294 0.249 0.239 0.145 0.151 0.098 0.099	1.142 0.120 0.050 0.067 2.372 2.694 2.154 1.561 1.390 0.865 0.604 0.519 0.294 0.199 0.209 0.184 0.151 0.106 0.108
19		0.351 0.192	0.171 0.164	0.083 0.084	0.090 0.087





むすべいひつ カコ

35/39 Figure 24

Fraction	volume	dilution	OD meas	sured at 450 nstruct 40 Type 1b	nm 62 Type 3a	63 Type 5a
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40	250 <i>µ</i> l	1/200	0.072 0.109 0.279 0.093 0.080 0.251 3 3 3 2.227 0.263 0.071 0.103 0.045 0.045 0.045 0.045 0.045 0.046	0.130 0.293 0.249 0.151 0.266 0.100 1.649 3 3 3 1.921 0.415 0.172 0.054 0.045 0.047 0.045 0.047 0.048 0.048 0.049	0.096 0.084 0.172 0.297 0.438 0.457 0.722 2.526 3 2.649 1.424 0.356 0.154 0.096 0.045 0.045 0.045 0.045 0.045 0.046 0.047 0.050 0.048	0.051 0.052 0.052 0.054 0.056 0.066 0.669 2.345 2.580 1.333 0.162 0.064 0.057 0.051 0.046 0.046 0.046 0.047 0.057 0.049




FIGURE 25




Figure 25




Figure 27





Figure 28



Lane 1: Crude Lysate

- Lane 2: Flow through Lentil Chromatography
- Lane 3: Wash with EMPIGEN Lentil Chromatography
- Lane 4: Eluate Lentil Chromatography
- Lane 5: Flow through during concentration lentil cluate -
- Lanc of Pool of Fiafter Size Exclusion Chromatography

Figure 29: Western Blot Analysis with anti-E1 mouse monoclonal 5E1A10



41/59





FIGURE 30

#### A: NON - REDUCED






FIGURE 31





FIGURE 32


#### FIGURE 33: SILVER STAIN OF PURIFIED E2



1. 30 mM IMIDAZOLE WASH NI-IMAC 2. 0.5 ug E2



45 139 Figure 34




No.	Ret.	Peak start (ml)	Peak end (ml)	Dur (ml)	Area (ml≅mAU)	Height (mAU)
1	-0.45	-0.46	-0.43	0.04	0.0976	4,579
2	1.55	0.75	3.26	2.51	796.4167	889.377
3	3.27	3.26	3.31	0.05	0.0067	0.224
4	3.33	3.32	3.33	0.02	0.0002	0.018

Total number of detected peaks = 4
Total Area above baseline = 0.796522 ml\*AU
Total area in evaluated peaks = 0.796521 ml\*AU
Ratio peak area / total area = 0.999999
Total peak duration = 2.613583 ml




## FIGURE 35A




47/59


### FIGURE 35B




## Eigure 36








**FIGURE 37** 





## Figure 38

# Relative Map Positions of anti-E2 monoclonal antibodies










nm00# Glycopeptidase F (PNGase F) OF HCV E1 ENVELOPE PROTEIN PARTIAL DEGLYCOSYLATION nm04 nwb um≯.0 um40.0 пшо Endoglycosidase H (Endo H) пшэ uma.0 nш*1*09 n*r*lg u43.0 nη0










Figure 40



↑ ₹ 30 cycles (1 min at 95°C; 1 min at 50°C; 1 min at 72°C) In Vitro Mutagenesis of HCV E1 glycoprotein First step of PCR amplification (Gly-# and Ovr-# primers) Bantll OVR-# Gly-# #-JAO GLY-# Eco R. 1 CIVI Fig. 42A



Buntl

EIGly-2 EIGly-3 EIGly-5 E1Gly-1 E1Gly-4 EIGly-6 **E2** Υ¥ In Vitro Mutagenesis of HCV E1 glycoprotein Banell 550 nt OVR-J CORE Fig. 43 82 85 83 84 98  $\overline{\infty}$ 





		HeLa cells		RK 13 cells		
		2 4 6 1 1 3 5 7		2 3 5 2		
80.0	_		- 80,0			80.0
49.5	_	:	<b>—</b> 49.5			49.5
32.5	_	April 1990	32.5	er i er	_	32.5
27.5	_		<b>— 27.</b> 5			27.5
18.5	_		<b>— 18.5</b>		_	18.5
		: -				

Figure 44A




Figure 418







Figure 45